<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.fibrogenesis.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Fibrogenesis &amp; Tissue Repair - Latest Articles</title>
        <link>http://www.fibrogenesis.com</link>
        <description>The latest research articles published by Fibrogenesis &amp; Tissue Repair</description>
        <dc:date>2013-05-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/10" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/9" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/8" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/7" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/6" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/5" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/4" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/3" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/2" />
                                <rdf:li rdf:resource="http://www.fibrogenesis.com/content/6/1/1" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/10">
        <title>Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts</title>
        <description>Background:
Platelet-derived growth factor (PDGF) signalling is essential for many key cellular processes in mesenchymal cells. As there is redundancy in signalling between the five PDGF ligand isoforms and three PDGF receptor isoforms, and deletion of either of the receptors in vivo produces an embryonic lethal phenotype, it is not know which ligand and receptor combinations mediate specific cellular functions. Fibroblasts are key mediators in wound healing and tissues repair. Recent clinical trials using broad spectrum tyrosine kinase inhibitors in fibrotic diseases have highlighted the need to further examine the specific cellular roles each of the tyrosine kinases plays in fibrotic processes. In this study we used PDGFR-specific neutralising antibodies to dissect out receptor-specific signalling events in vitro in fibroblasts in order to further understand key cellular processes involved in wound healing and tissue repair.
Results:
Neutralising antibodies against PDGFRs were shown to block signalling through PDGFRalpha and PDGFRbeta receptors, reduce human PDGF-AA and PDGF-BB-induced collagen gel remodelling in dermal fibroblasts, and reduce migration stimulated by all PDGF ligands in human dermal and lung fibroblasts.
Conclusions:
PDGFRalpha and PDGFRbeta neutralising antibodies can be a useful tool in studying PDGFR isoform-specific cellular events.</description>
        <link>http://www.fibrogenesis.com/content/6/1/10</link>
                <dc:creator>Johanna Donovan</dc:creator>
                <dc:creator>Xu Shiwen</dc:creator>
                <dc:creator>Jill Norman</dc:creator>
                <dc:creator>David Abraham</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:10</dc:source>
        <dc:date>2013-05-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-10</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-10-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2013-05-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/9">
        <title>Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases</title>
        <description>Background:
The proteoglycan biglycan (BGN) is involved in collagen fibril assembly and its fragmentation is likely to be associated with collagen turnover during the pathogenesis of diseases which involve dysregulated extracellular matrix remodeling (ECMR), such as rheumatoid arthritis (RA) and liver fibrosis. The scope of the present study was to develop a novel enzyme-linked immunosorbent assay (ELISA) for the measurement of a MMP-9 and MMP-12-generated biglycan neo-epitope and to test its biological validity in a rat model of RA and in two rat models of liver fibrosis, chosen as models of ECMR.
Results:
Biglycan was cleaved in vitro by MMP-9 and -12 and the 344&#8242;YWEVQPATFR&#8242;353 peptide (BGM) was chosen as a potential neo-epitope. A technically sound competitive ELISA for the measurement of BGM was generated and the assay was validated in a bovine cartilage explant culture (BEX), in a collagen induced model of rheumatoid arthritis (CIA) and in two different rat models of liver fibrosis: the carbon tetrachloride (CCL4)-induced fibrosis model, and the bile duct ligation (BDL) model. Significant elevation in serum BGM was found in CIA rats compared to controls, in rats treated with CCL4 for 16 weeks and 20 weeks compared to the control groups as well as in all groups of rats subject to BDL compared with sham operated groups. Furthermore, there was a significant correlation of serum BGM levels with the extent of liver fibrosis determined by the Sirius red staining of liver sections in the CCL4 model.
Conclusion:
We demonstrated that the specific tissue remodeling product of MMPs-degraded biglycan, namely the neo-epitope BGM, is correlated with pathological ECMR. This assay represents both a novel marker of ECM turnover and a potential new tool to elucidate biglycan role during the pathological processes associated with ECMR.</description>
        <link>http://www.fibrogenesis.com/content/6/1/9</link>
                <dc:creator>Federica Genovese</dc:creator>
                <dc:creator>Natasha Barascuk</dc:creator>
                <dc:creator>Lise Larsen</dc:creator>
                <dc:creator>Martin Larsen</dc:creator>
                <dc:creator>Arkadiusz Nawrocki</dc:creator>
                <dc:creator>Yili Li</dc:creator>
                <dc:creator>Qinlong Zheng</dc:creator>
                <dc:creator>Jianxia Wang</dc:creator>
                <dc:creator>Sanne Veidal</dc:creator>
                <dc:creator>Diana Leeming</dc:creator>
                <dc:creator>Morten Karsdal</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:9</dc:source>
        <dc:date>2013-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-9</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-9-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2013-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/8">
        <title>Autologous keratinocyte suspension in platelet concentrate accelerates and enhances wound healing &#191; a prospective randomized clinical trial on skin graft donor sites: platelet concentrate and keratinocytes on donor sites</title>
        <description>Background:
Wound healing involves complex mechanisms, which, if properly chaperoned, can enhance patient recovery. The abilities of platelets and keratinocytes may be harnessed in order to stimulate wound healing through the formation of platelet clots, the release of several growth factors and cytokines, and cell proliferation. The aim of the study was to test whether autologous keratinocyte suspensions in platelet concentrate would improve wound healing. The study was conducted at the Lausanne University Hospital, Switzerland in 45 patients, randomized to three different topical treatment groups: standard treatment serving as control, autologous platelet concentrate (PC) and keratinocytes suspended in autologous platelet concentrate (PC + K). Split thickness skin graft donor sites were chosen on the anterolateral thighs of patients undergoing plastic surgery for a variety of defects. Wound healing was assessed by the duration and quality of the healing process. Pain intensity was evaluated at day five.
Results:
Healing time was reduced from 13.9 +/- 0.5 days (mean +/- SEM) in the control group to 7.2 +/- 0.2 days in the PC group (P &lt; 0.01). An addition of keratinocytes in suspension further reduced the healing time to 5.7 +/- 0.2 days. Pain was reduced in both the PC and PC + K groups. Data showed a statistically detectable advantage of using PC + K over PC alone (P &lt; 0.01).
Conclusion:
The results demonstrate the positive contribution of autologous platelets combined with keratinocytes in stimulating wound healing and reducing pain. This strikingly simple approach could have a significant impact on patient care, especially critically burned victims for whom time is of the essence.Clinical trial registry information: Protocol Record Identification Number: 132/03Registry URL: http://www.clinicaltrials.gov</description>
        <link>http://www.fibrogenesis.com/content/6/1/8</link>
                <dc:creator>Samia Guerid</dc:creator>
                <dc:creator>Salim Darwiche</dc:creator>
                <dc:creator>Mette Berger</dc:creator>
                <dc:creator>Lee Ann Applegate</dc:creator>
                <dc:creator>Messod Benathan</dc:creator>
                <dc:creator>Wassim Raffoul</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:8</dc:source>
        <dc:date>2013-04-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-8</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-8-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2013-04-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/7">
        <title>Cyclosporin A reduces matrix metalloproteinases and collagen expression in dermal fibroblasts from regenerative FOXN1 deficient (nude) mice</title>
        <description>Background:
Cyclosporin A (CsA), an immunosuppressive agent modifies the wound healing process through an influence on extracellular matrix metabolism. We have compared the effects of CsA on dermal fibroblasts from nude (FOXN1 deficient) mice, a genetic model of skin scarless healing, and from control (C57BL/6&#8201;J (B6) mice to evaluate metabolic pathways that appear to have important roles in the process of scarless healing/regeneration.
Results:
High levels of matrix metalloproteinases (MMPs) and collagen III expression in dermal fibroblasts from nude (regenerative) mice were down-regulated by CsA treatment to the levels observed in dermal fibroblasts from B6 (non-regenerative) mice. In contrast, dermal fibroblasts from control mice respond to CsA treatment with a minor reduction of Mmps mRNA and 2.5-fold increase expression of collagen I mRNA. An in vitro migratory assay revealed that CsA treatment profoundly delayed the migratory behavior of dermal fibroblasts from both nude and control mice.
Conclusion:
The data suggest that by alternation of the accumulation of extracellular matrix components CsA treatment stimulates the transition from a scarless to a scar healing.</description>
        <link>http://www.fibrogenesis.com/content/6/1/7</link>
                <dc:creator>Barbara Gawronska-Kozak</dc:creator>
                <dc:creator>Heather Kirk-Ballard</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:7</dc:source>
        <dc:date>2013-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-7</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-7-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2013-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/6">
        <title>Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-&#223; and is required for TGF-&#223;-induced hydrogen peroxide production in fibroblasts</title>
        <description>Background:
Idiopathic pulmonary fibrosis (IPF) is a poorly understood progressive disease characterized by the recurrent damage of alveolar epithelial cells as well as inappropriate expansion and activation of fibroblasts resulting in pronounced extracellular matrix (ECM) deposition. Although recent studies have indicated the involvement of secreted protein acidic and rich in cysteine (SPARC), a matricellular protein regulating ECM deposition, in the pathogenesis of fibrosis, factors regulating SPARC expression or roles of SPARC in fibrosis have not been fully elucidated.
Results:
Among the profibrotic factors examined in cultured fibroblasts, we showed that SPARC expression was upregulated mainly by transforming growth factor (TGF)-&#946;. We also showed that expression of SPARC in the lung was upregulated in the murine bleomycin-induced pulmonary fibrosis model, which was inhibited by TGF-&#946; receptor I inhibitor. Knockdown of SPARC in fibroblasts using siRNA or treatment with the antioxidant N-acetylcysteine attenuated epithelial cell injury induced by TGF-&#946;-activated fibroblasts in a coculture system. We also demonstrated that SPARC was required for hydrogen peroxide (H2O2) production in fibroblasts treated with TGF-&#946;. Furthermore, TGF-&#946; activated integrin-linked kinase (ILK), which was inhibited by SPARC siRNA. Knockdown of ILK attenuated extracellular H2O2 generation in TGF-&#946;-stimulated fibroblasts. Our results indicated that SPARC is upregulated by TGF-&#946; and is required for TGF-&#946;-induced H2O2 production via activation of ILK, and this H2O2 production from fibroblasts is capable of causing epithelial cell injury.
Conclusions:
The results presented in this study suggest that SPARC plays a role in epithelial damage in the IPF lung via enhanced H2O2 production from fibroblasts activated by TGF-&#946;. Therefore, SPARC inhibition may prevent epithelial injury in IPF lung and represent a potential therapeutic approach for IPF.</description>
        <link>http://www.fibrogenesis.com/content/6/1/6</link>
                <dc:creator>Saiko Shibata</dc:creator>
                <dc:creator>Junichi Ishiyama</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:6</dc:source>
        <dc:date>2013-03-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-6</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-6-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2013-03-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/5">
        <title>Function and fate of myofibroblasts after myocardial infarction</title>
        <description>The importance of cardiac fibroblasts in the regulation of myocardial remodelling following myocardial infarction (MI) is becoming increasingly recognised. Studies over the last few decades have reinforced the concept that cardiac fibroblasts are much more than simple homeostatic regulators of extracellular matrix turnover, but are integrally involved in all aspects of the repair and remodelling of the heart that occurs following MI. The plasticity of fibroblasts is due in part to their ability to undergo differentiation into myofibroblasts. Myofibroblasts are specialised cells that possess a more contractile and synthetic phenotype than fibroblasts, enabling them to effectively repair and remodel the cardiac interstitium to manage the local devastation caused by MI. However, in addition to their key role in cardiac restoration and healing, persistence of myofibroblast activation can drive pathological fibrosis, resulting in arrhythmias, myocardial stiffness and progression to heart failure. The aim of this review is to give an appreciation of both the beneficial and detrimental roles of the myofibroblast in the remodelling heart, to describe some of the major regulatory mechanisms controlling myofibroblast differentiation including recent advances in the microRNA field, and to consider how this cell type could be exploited therapeutically.</description>
        <link>http://www.fibrogenesis.com/content/6/1/5</link>
                <dc:creator>Neil Turner</dc:creator>
                <dc:creator>Karen Porter</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:5</dc:source>
        <dc:date>2013-03-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-5</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-5-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2013-03-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/4">
        <title>Comparison of acute proton, photon, and low-dose priming effects on genes associated with extracellular matrix and adhesion molecules in the lungs</title>
        <description>Background:
Crew members on space missions inevitably are exposed to low background radiation and can receive much higher doses during solar particle events (SPE) that consist primarily of protons. Ionizing radiation could cause lung pathologies. Cell adhesion molecules (CAM) are believed to participate in fibrogenesis. Interactions between CAM and extracellular matrix (ECM) affect epithelial repair mechanisms in the lung. However, there are very limited data on biological effects of protons on normal lung tissue. Numerous reports have shown that exposure to low-dose/low-dose-rate (LDR) radiation can result in radioadaptation that renders cells more resistant to subsequent acute radiation. The goal of this study was to compare expression of genes associated with ECM and CAM, as well as critical profibrotic mediators, in mouse lungs after acute irradiation with photons and protons, and also determine whether pre-exposure to LDR &#947;-rays induces an adaptive effect.
Results:
Overall, a marked difference was present in the proton vs. photon groups in gene expression. When compared to 0 Gy, more genes were affected by protons than by photons at both time points (11 vs. 6 on day 21 and 14 vs. 8 on day 56), and all genes affected by protons were upregulated. Many genes were modulated by LDR &#947;-rays when combined with photons or protons. Col1a1, mmp14, and mmp15 were significantly upregulated by all radiation regimens on day 21. Similarly, the change in expression of profibrotic proteins was also detected after acute and combination irradiation.
Conclusion:
These data show that marked differences were present between acutely delivered protons and photons in modulating genes, and the effect of protons was more profound than that of photons. Pre-exposure to LDR &#947;-rays &#8216;normalized&#8217; some genes that were modified by acute irradiation.</description>
        <link>http://www.fibrogenesis.com/content/6/1/4</link>
                <dc:creator>Jian Tian</dc:creator>
                <dc:creator>Sisi Tian</dc:creator>
                <dc:creator>Daila Gridley</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:4</dc:source>
        <dc:date>2013-02-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-4</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-4-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2013-02-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/3">
        <title>The 22nd annual meeting of the European Tissue Repair Society (ETRS) in Athens, Greece</title>
        <description>The 22nd Annual Meeting of the European Tissue Repair Society, Athens, Greece, October 4 to 5, 2012 informed about pathophysiological mechanisms in tissue repair and on the development of clinical treatments of chronic wounds, fibrosis, and cancer, considering recent advances in molecular biology and biotechnology.</description>
        <link>http://www.fibrogenesis.com/content/6/1/3</link>
                <dc:creator>Boris Hinz</dc:creator>
                <dc:creator>Magda Ulrich</dc:creator>
                <dc:creator>Hilde Beele</dc:creator>
                <dc:creator>Dimitris Kletsas</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:3</dc:source>
        <dc:date>2013-02-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-3</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-3-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2013-02-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/2">
        <title>Serum amyloid P inhibits granulocyte adhesion</title>
        <description>Background:
The extravasation of granulocytes (such as neutrophils) at a site of inflammation is a key aspect of the innate immune system. Signals from the site of inflammation upregulate granulocyte adhesion to the endothelium to initiate extravasation, and also enhance granulocyte adhesion to extracellular matrix proteins to facilitate granulocyte movement through the inflamed tissue. During the resolution of inflammation, other signals inhibit granulocyte adhesion to slow and ultimately stop granulocyte influx into the tissue. In a variety of inflammatory diseases such as acute respiratory distress syndrome, an excess infiltration of granulocytes into a tissue causes undesired collateral damage, and being able to reduce granulocyte adhesion and influx could reduce this damage.
Results:
We found that serum amyloid P (SAP), a constitutive protein component of the blood, inhibits granulocyte spreading and granulocyte adhesion to extracellular matrix components. This indicates that in addition to granulocyte adhesion inhibitors that are secreted during the resolution of inflammation, a granulocyte adhesion inhibitor is present at all times in the blood. Although SAP affects adhesion, it does not affect the granulocyte adhesion molecules CD11b, CD62L, CD18, or CD44. SAP also has no effect on the production of hydrogen peroxide by resting or stimulated granulocytes, or N-formyl-methionine-leucine-phenylalanine (fMLP)-induced granulocyte migration. In mice treated with intratracheal bleomycin to induce granulocyte accumulation in the lungs, SAP injections reduced the number of granulocytes in the lungs.
Conclusions:
We found that SAP, a constitutive component of blood, is a granulocyte adhesion inhibitor. We hypothesize that SAP allows granulocytes to sense whether they are in the blood or in a tissue.</description>
        <link>http://www.fibrogenesis.com/content/6/1/2</link>
                <dc:creator>Anu Maharjan</dc:creator>
                <dc:creator>David Roife</dc:creator>
                <dc:creator>Derrick Brazill</dc:creator>
                <dc:creator>Richard Gomer</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:2</dc:source>
        <dc:date>2013-01-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-2</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-2-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2013-01-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.fibrogenesis.com/content/6/1/1">
        <title>HDAC inhibitors in experimental liver and kidney fibrosis</title>
        <description>Histone deacetylase (HDAC) inhibitors have been extensively studied in experimental models of cancer, where their inhibition of deacetylation has been proven to regulate cell survival, proliferation, differentiation and apoptosis. This in turn has led to the use of a variety of HDAC inhibitors in clinical trials. In recent years the applicability of HDAC inhibitors in other areas of disease has been explored, including the treatment of fibrotic disorders. Impaired wound healing involves the continuous deposition and cross-linking of extracellular matrix governed by myofibroblasts leading to diseases such as liver and kidney fibrosis; both diseases have high unmet medical needs which are a burden on health budgets worldwide. We provide an overview of the potential use of HDAC inhibitors against liver and kidney fibrosis using the current understanding of these inhibitors in experimental animal models and in vitro models of fibrosis.</description>
        <link>http://www.fibrogenesis.com/content/6/1/1</link>
                <dc:creator>Katrien Van Beneden</dc:creator>
                <dc:creator>Inge Mannaerts</dc:creator>
                <dc:creator>Marina Pauwels</dc:creator>
                <dc:creator>Christiane Van den Branden</dc:creator>
                <dc:creator>Leo van Grunsven</dc:creator>
                <dc:source>Fibrogenesis &amp; Tissue Repair 2013, null:1</dc:source>
        <dc:date>2013-01-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1755-1536-6-1</dc:identifier>
                                <prism:require>/content/figures/1755-1536-6-1-toc.gif</prism:require>
                <prism:publicationName>Fibrogenesis &amp; Tissue Repair</prism:publicationName>
        <prism:issn>1755-1536</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2013-01-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
